A chemical conjugate of the tick P0 peptide is efficacious against Amblyomma mixtum

2020 ◽  
Vol 67 (S2) ◽  
pp. 175-177 ◽  
Author(s):  
Alina Rodríguez‐Mallon ◽  
Pedro E. Encinosa Guzmán ◽  
Yamil Bello Soto ◽  
Karen Rosales Perdomo ◽  
Carlos Montero Espinosa ◽  
...  
Keyword(s):  
Chemical Conjugate

scholarly journals Synthesis and Characterization of a Homogeneous Chemical Conjugate Between Basic Fibroblast Growth Factor and Saporin

1995 ◽  
Vol 234 (3) ◽  
pp. 706-713 ◽  
Author(s):  
Ying Ji Buechler ◽  
Barbara A. Sosnowski ◽  
Kimberly D. Victor ◽  
Zahra Parandoosh ◽  
Stuart J. Bussell ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Basic Fibroblast Growth Factor ◽  
Synthesis And Characterization ◽  
Fibroblast Growth ◽  
Chemical Conjugate ◽  
Homogeneous Chemical

scholarly journals Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases

2020 ◽  
pp. 174-180
Author(s):  
L. Yu. Vladimirova ◽  
I. L. Popova ◽  
N. A. Abramova ◽  
M. A. Teplyakova ◽  
N. M. Tikhanovskaya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stereotactic Radiosurgery ◽  
Whole Brain Radiotherapy ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Luminal B ◽  
Her2 Positive Breast Cancer ◽  
Brain Radiotherapy ◽  
Chemical Conjugate ◽  
Positive Breast Cancer

Patients with brain metastases of HER2-positive breast cancer (BC) is a special group of patients who are difficult to treat and have a short life expectancy. The possibilities of whole brain radiotherapy, stereotactic radiosurgery and surgery in such patients are rather limited. Trastuzumab emtansine (T-DM1) showed potential activity in this subset of patients. T-DM1 is an antibody-chemical conjugate (ADC) that delivers directly to HER2-positive cancer cells, thereby limiting damage to healthy tissue. At this point, the efficacy of trastuzumab emtansine has been demonstrated in several randomized trials as a second and subsequent lines of therapy for advanced breast cancer with a favorable toxicity profile of the drug. This article describes a clinical case of a patient with luminal B HER-2 positive breast cancer who, underwent stereotactic radiosurgery and was treated with trastuzumab emtansine as a the second line of treatment for disease progression with metastatic brain lesions after trastuzumab/pertuzumab-containing therapy. Partial regression of metastases with long-term duration of the effect was achieved treatment with trastuzumab emtazine has been being continued for 24 months. Tolerability of therapy was good: thrombocytopenia 2 degree was the main among side effects. The effect has been persisted for 2 years and the patient continues the treatment. Discussion of the results of real clinical practice with well-known studies was carried out.

Heparin–deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity

2006 ◽  
Vol 114 (3) ◽  
pp. 300-306 ◽  
Author(s):  
Kyeongsoon Park ◽  
Gee Young Lee ◽  
Yoo-Shin Kim ◽  
Mikyung Yu ◽  
Rang-Woon Park ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Anticancer Drug ◽  
Deoxycholic Acid ◽  
Drug Carrier ◽  
Chemical Conjugate

Intracellular pH-sensitive delivery CaCO3 nanoparticles templated by hydrophobic modified starch micelles

RSC Advances ◽  
2014 ◽  
Vol 4 (21) ◽  
pp. 10841-10844 ◽  
Author(s):  
Xiaoying Ying ◽  
Chunlei Shan ◽  
Kuaikuai Jiang ◽  
Zhong Chen ◽  
Yongzhong Du
Keyword(s):  
Intracellular Ph ◽  
Octanoic Acid ◽  
Ph Sensitive ◽  
Release Profile ◽  
Modified Starch ◽  
Caco3 Nanoparticles ◽  
Acid Ph ◽  
Chemical Conjugate ◽  
Micelle Solution

CaCO3 nanoparticles were prepared using starch–octanoic acid chemical conjugate micelle solution as a template to improve the acid pH sensitive release profile.

Chemical Conjugate TMV−Peptide Bivalent Fusion Vaccines Improve Cellular Immunity and Tumor Protection

2006 ◽  
Vol 17 (5) ◽  
pp. 1330-1338 ◽  
Author(s):  
Alison A. McCormick ◽  
Tina A. Corbo ◽  
Sherri Wykoff-Clary ◽  
Kenneth E. Palmer ◽  
Gregory P. Pogue
Keyword(s):  
Cellular Immunity ◽  
Chemical Conjugate ◽  
Tumor Protection

scholarly journals Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas

Blood ◽  
2006 ◽  
Vol 108 (1) ◽  
pp. 328-336 ◽  
Author(s):  
John M. Pagel ◽  
Yukang Lin ◽  
Nathan Hedin ◽  
Anastasia Pantelias ◽  
Donald Axworthy ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Athymic Mice ◽  
Single Chain ◽  
Single Chain Antibody ◽  
Normal Organ ◽  
Normal Tissues ◽  
Non Hodgkin Lymphoma ◽  
Chemical Conjugate ◽  
Anti Cd20 ◽  
Cd20 Antibodies

The efficacy of radioimmunotherapy (RIT) for patients with relapsed non-Hodgkin lymphoma (NHL) is limited by nonspecific delivery of radiation to normal tissues due to the long circulating half-life of radiolabeled anti-CD20 antibodies (Abs). Pretargeted RIT using a covalent conjugate of the 1F5 anti-CD20 Ab with streptavidin (SA) has been shown to augment the efficacy of RIT and decrease toxicity compared with a directly labeled 1F5 Ab. We have engineered a tetravalent singlechain 1F5 (scFv)4SA fusion protein and compared it to the 1F5-SA conjugate. Athymic mice bearing Ramos lymphoma xenografts received either the conjugate or fusion protein, followed 20 hours later by a biotin-N-acetyl-galactosamine clearing agent, followed 4 hours later by 111In-DOTA-biotin. After 24 hours, 11.4% ± 2.1% of the injected dose of radionuclide was present per gram of tumor (% ID/g) using 1F5 (scFv)4SA compared with 10.8% ± 2.5% ID/g with 1F5 Ab-SA. Superior tumor-to-normal organ ratios of radioactivity were consistently seen using the fusion protein compared with the chemical conjugate (eg, tumor-to-blood ratio > 65:1 after 48 hours with the fusion protein, but < 7:1 with the conjugate). More than 90% of lymphomabearing mice could be cured with minimal toxicity using either reagent followed by 1200 μCi (44.4 MBq) 90Y-DOTA-biotin. (Blood. 2006;108:328-336)

Sign in / Sign up

Export Citation Format

Share Document